参考文献 References
[1] Beck-NielsenSS，Brock-JacobsenB, Gram J, eta1. Incidenceand prevalence ofnutritionaland hereditary ricketsin Southern Denmark[J]．EurJEndocrino1, 2009, 160: 491-497．
[2] Beck-Nielsen SS, Brixen K, Gram J, et al. Mutational analysis of PHEX, FGF23, DMP1, SLC34A3 and CLCN5 in patients with hypophosphatemic rickets[J]. J Hum Genet, 2012,57:453-458.
[3] Sun Y, Wang O, Xia W, et al. FGF23 analysis of a Chinese family with autosomal dominant hypophosphatemic rickets[J]. J Bone Miner Metab,2012,30(1):78-84.
[4] Xia W, Meng X, Jiang Y, et al. Three novel mutations of the PHEX gene in three Chinese families with X-linked dominant hypophosphatemic rickets[J]. Calcif Tissue Int,2007,81(6):415-420.
[5] Yuan B, Feng JQ, Bowman S, et al. Hexa-D-arginine treatment increases 7B2•PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype[J]. J Bone Miner Res, 2013,28(1):56–72.
[6] Miyagawa K, Yamazaki M, Kawai M, et al. Dysregulated gene expression in the primary osteoblasts and osteocytes isolated from hypophosphatemic Hyp mice[J]. PloS One,2014,9(4):e93840.
[7] Yamazaki Y, Okazaki R, Shibata M, et al. Increased circulatory level of biologically active full-length FGF23 in patients with hypophosphatemic rickets/osteomalacia[J]. J Clin Endocrinol Metab,2002,87(11):4957-4960.
[8] Carpenter TO, Insogna KL, Zhang JH, et al.Girculating level of soluble klotho and FGF23 in X-linnked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status[J]. J Clin Endocrinol Metab, 2010,95:E352-E357.
[9] Morey M, Castro-Feijoo L, Barreiro J, et al. Genetic diagnosis of X-linked dominant Hypophosphatemic Rickets in a cohort study：tubular reabsorption of phosphate and 1,25(OH )2D serum levels are associated with PHEX mutation type[J]. BMC Med Genet, 2011, 12:116.
[10] Ranch D, Zhang MYH, Portale AA, et al. Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice[J]. J Bone Miner Res,2011,26(8):1883-1890.
[11] Cong Zhang, Zhen Zhao, Yue Sun, et al. Clinical and genetic analysis in a large Chinese cohort of patients with X-linked hypophosphatemia[J].Bone, 2019,121:212-220.
[12] 宋莹，麻宏伟，黎芳，等. X-连锁低磷性佝偻病的基因突变分析[J]. 中国当代儿科杂志, 2013,15(11):928-931.
[13] Capelli S, Donghi V, Maruca K, et al. Clinical and molecular heterogeneity in a large series of patients with hypophosphatemic rickets [J].Bone,2015,79:143-149.
[14] Song HR, Park JW, Cho DY, et al. PHEX gene mutations and genotype-phenotype analysis of Korean patients with hypophosphatemic rickets[J]. J Korean Med Sci,2007,22(6):981-986.
[15] Yue H, Yu JB, He JW, et al. Identification of two novel mutation in the PHEX gene in Chinese patients with hypophosphatemic rickets/osteomalacia[J]. Plos One, 2014, 9(5): e97830.
[16] CHO HY, LEE BH, KANG JH, et al. A clinical and molecular genetic study of hypophosphatemic rickets in children[J]. Pediatr Res, 2005,58(2):329-333.
[17] Agnès Linglart, Martin Biosse-Duplan, Karine Briot,et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood[J]. Endocr Connect, 2014, 14, 3(1): R13-30.
[18] Hélène Che, Christian Roux, Adrien Etcheto, et al. Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms[J].Eur J Endocrinol, 2016, 174(3):325-333.
[19] Rafael A Vega, Charles Opalak, Raymond J Harshbarger, et al. Hypophosphatemic rickets and craniosynostosis: a multicenter case series[J]. J Neurosurg Pediatr, 2016, 17(6): 694-700.
[20] Rothenbuhler A, Fadel N, Debza Y, et al. High Incidence of Cranial Synostosis and Chiari I point mutations and detection of large deletions by MLPA in patients with X-linked hypophosphatemic rickets[J]. Calcif Tissue Int, 2009, 85(3):211–220.
[21] Thacher TD, Fischer PR, Pettifor JM, et al. Radiographic scoring method for the assessment of the severity of nutritional rickets[J]. J Trop Pediatr,2000,46(3):132-139.
[22] Guven A, Al-Rijjal RA, BinEssa HA, et al. Mutational analysis of PHEX, FGF23 and CLCN5 in patients with hypophosphataemic rickets[J]. Clin Endocrinol (Oxf), 2017,87(1):103–112.
[23] Ruppe MD, Brosnan PG, Au KS, et al. Mutational analysis of PHEX, FGF23 and DMP1 in a cohort of patients with hypophosphatemic rickets[J]. Clin Endocrinol (Oxf), 2011,74(3):312–318.
[24] Ma SL, Vega-Warner V, Gillies C,et al. Whole Exome Sequencing Reveals Novel PHEX Splice Site Mutations in Patients with Hypophosphatemic Rickets[J]. PloS One, 2015,10(6):e0130729.
[25] Zou M, Buluş D, Al-Rijjal RA, et al. Hypophosphatemic rickets caused by a novel splice donor site mutation and activation of two cryptic splice donor sites in the PHEX gene[J]. J Pediatr Endocrinol Metab, 2015, 28(1–2): 211–216.
[26] Verge CF, Lam A, Simpson JM, et al. Effects of therapy in X-linked hypophosphatemic rickets[J]. N Engl J Med, 1991, 325:1843.
[27] Seikaly M, Browne R, Baum M. Nephrocalcinosis is associated with renal tubular acidosis in children with X-linked hypophosphatemia[J]. Pediatrics,1996,97:91.
[28] Alon U, Donaldson DL, Hellerstein S, et al. Metabolic and histologic investigation of the nature of nephrocalcinosis in children with hypophosphatemic rickets and in the hypmouse[J]. J Pediatr, 1992,120:899.
[29] Tieder M, Blonder J, Strauss S, et al. Hyperoxaluria is not a cause of nephrocalcinosis in phosphate-treated patients with hereditary hypophosphatemic rickets[J]. Nephron,1993,64:526.
[30] Nielsen LH, Rahbek ET, Beck-Nielsen SS, Christesen HT. Treatment of hypophosphataemic rickets in children remains a challenge[J]. Dan Med J, 2014, 61(7):A4874.
[31] Rafaelsen S, Johansson S, Raeder H, et al. Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications[J]. Eur J Endocrinol, 2016, 174(2): 125-136.
[32] Carpenter TO, Mitnick MA, Ellison A, et al. Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia[J]. J Clin Endocrinol Metab, 1994,78:1378.
[33] DeLacey S, Liu Z, Broyles A, et al. Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients[J]. Bone, 2019, 127:386-392.
[34] Carpenter TO, Imel EA, Holm IA, et al. A clinician’s guide to X-linked hypophosphatemia[J]. J Bone Miner Res,2011,26(7):1381-1388.
[35] Makitie O, Doria A, Kooh W, et al. Early treatmetn improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets[J]. J Clin Endocrinol Metab, 2003,88(8):3591-3597.
[36] Quinlan C, Guegan K, Offiah A, et al. Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment[J]. Pediatr Nephrol, 2012,27(4):581-588.
[37] NIELSEN LH, RAHBEK ET, BECK-HIELSEN SS, et al. Treatment of hypophosphatemic rickets in children remains a challenge[J]. Dan Med J, 2014,61(7): A4874.
[38] JEHAN F, GAUCHER C, HGUYEN TM, et al. Vitamin D receptor genotype in hypophosphatemic rickets as a predictor of growth and response to treatment[J]. J Clin Endocrinol Metab, 2008,93(12):4672-4682.
[39] 魏丽亚, 巩纯秀, 曹冰燕, 等. 儿童X连锁显性遗传性低磷血症性佝偻病临床及基因分析. 中华儿科杂志,2021,59(8): 678-683.
[40] https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761068s000lbl.pdf
[41] https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761068s004lbl.pdf
[42] Haffner D, Emma F, Eastwood DM, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia[J]. Nat Rev Nephrol, 2019, 15(7): 435-455.
[43] Imel EA, Glorieux FH, Whyte MP, et al. Burosumab Versus conventional therapy in children with X-linked hypophosphatemia: a randomised, active-controlled, open-label, phase 3 trial[J]. Lancet, 2019, 393 (10189): 2416.
[44] Carpenter TO, Whyte MP, Imel EA, et al. Burosumab therapy in children with X-linked hypophosphatemia[J]. N Engl J Med, 2018,378:1987-1998.
[45] Whyte MP, Carpenter TO, Gottesman GS, et al. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 tiral[J]. Lancet Diabetes Endocrinol, 2019, 7: 189-199.
[46] Martin Ramos S, Cil-Calvo M, Roldan V, et al. Positive response to one-year treatment with burosumab in pediatric patients with X-linked hypophosphatemia[J]. Front Pediatr, 2020,8:48.
[47] PETERSEN DJ, BONIFACE AM, SCHRANCK FW, et al. X-linked hypophosphatemic rickets: a study(with literature review) of linear growth response to calcitriol and phosphate therapy[J]. J Bone Miner Res, 1992,7(6):583-597.
[48] AHFFNER D, WEINFURTH A, MANZ F, et al. Long-term outcome of paediatric patients with hereditary tubular disorders[J]. Nephron, 1999,83(3):250-260.
[49] Anya Rothenbuhler, Laure Esterle, Iva Gueorguieva, et al. Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR)[J]. Growth Horm IGF Res, 2017, 36: 11–15.
[50] Haffner D, Nissel R, Wühl E, et la. Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets[J]. Pediatrics, 2004,113(6):e593.
[51] Nadine Meyerhoff, Dieter Haffner, Hagen Staude, et al. Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets[J]. PediatrNephrol,2018, 33: 447–456.
[52] G I Baroncelli, S Bertelloni, C Ceccarelli, et al. Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets[J].J Pediatr, 2001,138(2):236-243.
[53] A Gizard, A Rothenbuhler, Z Pejin, et al. Outcomes of orthopedic surgery in a cohort of 49 patients with X-linked hypophosphatemic rickets (XLHR)[J]. Endocr Connect, 2017,6(8):566-573.
[54] M Kocaoglu, F E Bilen, C Sen, et al.Combined technique for the correction of lower-limb deformities resulting from metabolic bone disease[J]. J Bone Joint Surg Br, 2011,93(1):52-56.
[55] A Horn, J Wright, D Bockenhauer, et al. The orthopaedic management of lower limb deformity in hypophosphataemic rickets[J]. J Child Orthop, 2017,11(4):298-305.
[56] Horn A, Wright J, Bockenhauer D, et al. The orthopaedic management of lower deformity in hypophosphatemic rickets[J]. J Child Orthop,2017,11(4): 298-305.